Abiomed (NASDAQ:ABMD) reported Q1 EPS of $1.25, $0.19 better than the analyst estimate of $1.06. Revenue for the quarter came in at $277 million versus the consensus estimate of $278.98 million.
Abiomed (NASDAQ:ABMD) reported Q1 EPS of $1.25, $0.19 better than the analyst estimate of $1.06. Revenue for the quarter came in at $277 million versus the consensus estimate of $278.98 million.